乌鸦传媒

In this exclusive 乌鸦传媒 video, Tanya Dorff, MD, of City of Hope in Duarte, California, discusses two prostate cancer immunotherapy studies presented at the recent American Society of Clinical Oncology (ASCO) annual meeting.

Following is a transcript of her remarks:

There were two interesting prostate cancer immunotherapy studies at this meeting presented in the rapid oral session. One was the . It's a bispecific T-cell engager targeting DLL3 for neuroendocrine prostate cancer. Unfortunately, the response rate was relatively low and the rate of cytokine release syndrome was fairly high -- what we are used to seeing with other bispecific antibodies in this disease. So it's unlikely that this will become a therapeutic that we can use for this population that's a tremendous unmet need.

But the other antibodies that are T-cell engaging that are being used for adenocarcinoma, the prostate, things like AMG 160, which we recently published in , and the ongoing AMG 509, do seem to have higher levels of efficacy. So this is a modality that I think will come to be used in the clinic in prostate cancer treatment in the future.

The other really interesting abstract was , which was looking at using an immune selection biomarker to treat patients with mCRPC [metastatic castration-resistant prostate cancer] with [ipilimumab (Yervoy)-nivolumab (Opdivo)]. So previously ipi-nivo has been difficult to tolerate in mCRPC and not as effective as we would like, but this immune selection biomarker seems to have done a good job. The response rate was considerably better, about 44%. Toxicity was more manageable in this population for whatever reason.

But, still, I think there are other selectors that people should remember. So we recently published that for high tumor mutational burden, which is on-label for pembrolizumab [Keytruda], about 50% of mCRPC patients with that biomarker respond to single agent, which has a much better toxicity profile.

Comment